Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsija - antiepileptics, - levetiracetam actavis group je indiciran kot monoterapija pri zdravljenju napadov s parcialnim nastopom s sekundarno generalizacijo ali brez nje pri bolnikih od 16. leta starosti z novo diagnosticirano epilepsijo. levetiracetam actavis group je označen kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle, otroke in dojenčke od 1 meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - imatinib - filmsko obložena tableta - imatinib 400 mg / 1 tableta - imatinib

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - imatinib - filmsko obložena tableta - imatinib 300 mg / 1 tableta - imatinib

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - imatinib - filmsko obložena tableta - imatinib 200 mg / 1 tableta - imatinib

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - imatinib - filmsko obložena tableta - imatinib 100 mg / 1 tableta - imatinib

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf - sildenafil - erektilna disfunkcija - urološki - zdravljenje moških z erektilno disfunkcijo, ki ni sposobna doseči ali vzdrževati erekcije penisa, ki zadošča za zadovoljivo spolno delovanje. da bi sildenafil actavis, da bo učinkovito, spolne stimulacije je potrebno.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminiki za sistemsko zdravljenje, - zdravljenje alergijskega rinitisa in urtikarije.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. učinek imatinib na izid presaditev kostnega mozga, ni bilo določeno. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. izkušnje z imatinib pri bolnikih z mds/mpd, povezanih z pdgfr gena ponovno ureditev je zelo omejena. ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsija - antiepileptics, - levetiracetam actavis je označen kot monoterapije pri zdravljenju zasegov delno nastopom z ali brez sekundarnega posploševanje pri bolnikih od 16 let z novo diagnosticirano epilepsijo. levetiracetam actavis je označen kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle, otroke in dojenčke od enega meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena (glej poglavje 4.